Navigation Links
Medifast, Inc. Announces Acceptance for Publication of Clinical Efficacy Study
Date:10/15/2007

Study of Medifast's effectiveness for weight control in patients with type

2 diabetes has been accepted for publication

OWINGS MILLS, Md., Oct. 15 /PRNewswire-FirstCall/ -- Medifast, Inc. (NYSE: MED) today announced that a study conducted by researchers at the Johns Hopkins University Bloomberg School of Public Health has been accepted for publication in a peer-reviewed journal which is scheduled for release in an early 2008 issue. The study compared Medifast's effectiveness for weight control to the standard American Diabetes Association (ADA) recommended dietary guidelines.

"Weight loss is critical for controlling type 2 diabetes," said Michael S. McDevitt, Chief Executive Officer, Medifast, Inc. "Medifast is proud that our products are effective for people who suffer from this disease, and we will continue to work toward improving the health of people with type 2 diabetes."

For more than 25 years Medifast has been prescribed by practitioners as a safe and effective program that yields significant results either alone, or as a complementary low-calorie program with drug therapy. The Medifast brand will be further validated in the medical community, and by consumers, by a second new study recently submitted for publication. The second study which was conducted by researchers at a major university medical institution, shows favorable findings for the Medifast Program among individuals on appetite suppressant therapy.

The Medifast Program alone is proven to provide significant weight loss of 2-5 pounds per week. While the Company does not recommend the use of weight loss drugs, Medifast does recognize that diet pills are very much part of the landscape now and in the future. Medifast is a proven program that can ensure consumers are successful on drug therapy regimens that include a reduced calorie diet and lifestyle change in order to be effective. Medifast also works well with the current popular over-the-counter drug that recommends utilizing a low fat program.

The findings from studies at two university medical institutions only add to the medically approved history of the Medifast Program. Medifast has been recommended by over 15,000 physicians nationwide, and provides its customers with a network of health coaches and nutrition experts as well as a vast online support community.

More information regarding the inclusion of studies in peer-reviewed journals will become available at the time of publication.

About Medifast:

Medifast (NYSE: MED) is the leading easy-to-use, clinically proven portion-controlled weight loss program. Medifast has been recommended by 15,000 physicians and used by over one million customers. It is committed to enriching lives by providing innovative choices for lasting health. Medifast programs have been proven effective through studies by major university teaching hospitals. The company sells its products and programs via four unique distribution channels: 1) the web and national call centers, 2) national network of physicians, 3) medically supervised Medifast Weight Control Centers and 4) the Take Shape For Life direct-selling division, a network of health coaches. Medifast was founded in 1980 and is located in Owings Mills, Maryland. For more information log onto http://www.ChooseMedifast.com.


'/>"/>
SOURCE Medifast, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Sygnis Pharma AG announces date for presentation of clinical results
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016  Arkis BioSciences, ... less invasive and more durable cerebrospinal fluid treatments, ... funding.  The Series-A funding is led by Innova ... Fund, and other private investors.  Arkis, new financing ... instrumentation and the market release of its in-licensed ...
(Date:6/23/2016)... , June 23, 2016  In a startling report released today, ... their residents by lacking a comprehensive, proven plan to eliminate prescription ... definitive ranking of how states are tackling the worst drug crisis ... four states – Kentucky , New ... Vermont . Of the 28 failing states, three – ...
(Date:6/23/2016)... Bracket , a leading clinical trial technology and specialty ... Bracket eCOA (SM) 6.0, at the 52 nd ... in Philadelphia , Pennsylvania.  A demonstration of ... its kind to fully integrate with RTSM, will be held ... a flexible platform for electronic clinical outcomes assessments that is ...
Breaking Medicine Technology:
(Date:6/27/2016)... , ... June 27, 2016 , ... "FCPX editors can ... inside of Final Cut Pro X," said Christina Austin - CEO of Pixel Film ... Final Cut Pro X users can now reveal the media of their ...
(Date:6/26/2016)... ... ... Quality metrics are proliferating in cancer care, and are derived from many ... the beholder, according to experts who offered insights and commentary in the current issue ... the full issue, click here . , For the American Society of Clinical ...
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... ... fertility once they have been diagnosed with endometriosis. These women need a treatment ... also require a comprehensive approach that can help for preservation of fertility and ...
(Date:6/25/2016)... , ... June 25, 2016 , ... First Choice ... States, named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm ... Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical ...
(Date:6/24/2016)... ... 2016 , ... A recent article published June 14 on E ... goes on to state that individuals are now more comfortable seeking to undergo not ... as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians ...
Breaking Medicine News(10 mins):